• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ALL
Click for more information
0.55% 13,435

NZX All - Announcements

watchlist Created with Sketch. Add to my watchlist

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search

No announcements returned.

refresh Created with Sketch. REFRESH
 
(20min delay)
Last
13,435 		Change
-73.610(0.55%) 		Mkt cap ! n/a
Open High Low
13,508 13,508 13,426
ALL (NZSX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Argent hits rockchips up to 24g/t gold at Trunkey Creek, NSW Argent Minerals has unveiled rockchips containing gold grading up to 24g/t on-site its NSW-based Trunkey Creek project acreage.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Canada orders national security review over CGN's 11.26% opposition to Paladin-Fission deal Paladin has disclosed its attempted takeover of Fission Uranium Corp was blocked by a Chinese shareholder late last month.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.